Indian Journal of Urology
REVIEW ARTICLE
Year
: 2017  |  Volume : 33  |  Issue : 2  |  Page : 118--126

Systemic therapy in bladder cancer


Ian G Pinto 
 Department of Hematology and Medical Oncology, Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India

Correspondence Address:
Ian G Pinto
Department of Hematology and Medical Oncology, Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra
India

Systemic chemotherapy is essential for the management of muscle-invasive bladder cancer (MIBC) and metastatic bladder cancer (BCa). Neoadjuvant chemotherapy is key to the management of MIBC with many cisplatin-based regimens. Adjuvant chemotherapy may be considered for selected patients who did not receive neoadjuvant therapy. Systemic chemotherapy with radiotherapy is a critical component of a trimodal bladder-preserving approach and is superior to radiotherapy alone. Cisplatin-based chemotherapy has been the mainstay for metastatic BCa. Immunotherapy in the form of checkpoint inhibitors is a promising new drug for the treatment of BCa. Molecular characterization of each individual BCa is likely to lead to a target-directed therapeutic revolution.


How to cite this article:
Pinto IG. Systemic therapy in bladder cancer.Indian J Urol 2017;33:118-126


How to cite this URL:
Pinto IG. Systemic therapy in bladder cancer. Indian J Urol [serial online] 2017 [cited 2022 Nov 27 ];33:118-126
Available from: https://www.indianjurol.com/article.asp?issn=0970-1591;year=2017;volume=33;issue=2;spage=118;epage=126;aulast=Pinto;type=0